Related Experiment Video
Updated: May 22, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Recommendations for improving adherence to type 2 diabetes mellitus therapy--focus on optimizing insulin-based
1Washington State University, College of Pharmacy, 1505 Stadium Way, Pullman, WA 99164, USA. rkcamp@wsu.edu
The American Journal of Managed Care
|May 8, 2012
Summary
Patient education and new insulin therapies, including advanced formulations and pen delivery systems, can overcome challenges like fear and side effects. This improves treatment adherence and outcomes for type 2 diabetes mellitus (T2DM).
Area of Science:
- Endocrinology
- Pharmacology
- Patient Education
Background:
- Insulin is highly effective for diabetes management but faces resistance due to side effects like weight gain and hypoglycemia.
- Patient and provider perceptions often view insulin as a last resort or punishment, compounded by needle phobia.
Purpose of the Study:
- To explore how patient education and advancements in insulin therapy can overcome barriers to insulin use.
- To highlight the benefits of new insulin formulations and delivery systems for type 2 diabetes mellitus (T2DM) management.
Main Methods:
- Review of current insulin formulations (rapid-acting, long-acting analogues, premixed) and delivery systems (pens vs. vial/syringe).
- Emphasis on the role of patient education in improving self-management and coping skills for T2DM.
Main Results:
- New insulin formulations and pen delivery systems offer improved pharmacokinetic profiles, ease of use, discretion, and accurate dosing.
- Pen delivery systems are associated with greater patient adherence and better glycemic control compared to traditional vial and syringe methods.
- Educational initiatives are crucial for addressing knowledge gaps in diabetes self-management and coping.
Conclusions:
- Overcoming challenges in insulin therapy requires a combination of innovative formulations, user-friendly delivery systems, and comprehensive patient education.
- Appropriate use of insulin, coupled with robust educational programs, leads to improved treatment adherence, better health outcomes, and reduced healthcare costs for T2DM patients.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...